New drug products

In spite of the considerable progress in developing methods for total synthesis, this route to cephalosporins cannot compete with fermentation or penicillin rearrangement (see Sections 5.10.4.1 and 2) for the industrial production of cephalosporin antibiotics. While total synthesis does provide access to nuclear analogs not readily obtainable from fermentation products, none of the totally synthetic materials have displayed sufficient advantages to Warrant their development as new drug products (b-81MI51000). 

International Conference on Harmonisation Draft Guidance on Specifications Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products Chemical Substances Notice, Fed Regist. Docket No. 97D-0448, 1997. 

To determine whether human testing for a new drug or new drug product is reasonable, it is first necessary to conduct preclinical studies and to submit the IND. The necessary information needed to prepare the IND is outlined in Table 1. The IND is to contain information on appropriate prior animal studies for safety evaluation, any available clinical data, adequate drug identification and manufacturing instructions, and a detailed outline of the proposed clinical study, routs of administration, approximate number of patients to be used, and an estimate of the length of treatment and an environmental impact statement. 

While we cannot predict how these policies will play out in the years ahead, they will dramatically influence innovation, positively or negatively, in the future and the pharmaceutical industry that depends on innovation and the consequent supply of new drug products that depends on the pharmaceutical industry. 

Applications for FDA Approval to Market a New Drug, New Drug Product Exclusivity, (1999) CFR, Title 21, Part 314, Volume 5, Section 314.108. 

Validation of analytical procedures methodology Guideline on Impurities in New Drug Substances Guideline on Impurities in New Drug Products Availability Notice... 

ICH Topic Q6A. Note on Guidance Specifications test procedures and acceptance criteria for new drug substances and new drug products chemical substances. Oct 6, 1999. 

It is a general requirement for an optimal therapeutic effect that the active pharmaceutical ingredient (API) is delivered to the site of action in order to provide effective but not toxic concentration levels. Therefore, studies to measure BA are of great importance in order to support new drug product applications. Thus, data on the BA of orally administered drug products is a general requirement to the development... 

For new drug products with little or no effective patent life, generic firms are prohibited from filing an abbreviated new drug application within the first 5 years of the product life. Most European countries prohibit such filing within the first 10 years of market life. 

ICH Guideline Q3B(R) Impurities in New Drug Products (revised guideline), 2003. http //www.ich.org/pdfICH/Q3Bstep4.pdf. 

Impurities in new drug products Q3B (R2), International Conference on Harmonisation, 2006, http //www.ich.org/cache/compo/276-254-l.html... 

Pharmaceutical drug products have become increasingly important to providing consumers with a myriad of treatments and cures that increase life expeetaney and enhance lives. It is critieal to maintain appropriate incentives for the development of new drug products, because the neeessary research and development is risky and costly. Innovation in the pharmaeeutieal industry, spurred in part by eompetitive market forces, continues to bring enormous benefits to Americans. 

---